Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SDSean DevlinNKNeha KordeMSMichael Scordo

Discussion

Loading...

Member takes

Overview

Randomized trial found no difference in quality of life between daratumumab and lenalidomide maintenance in newly diagnosed multiple myeloma, indicating similar efficacy and tolerability.

Key Points

  • Maintenance therapy with daratumumab showed comparable effects on quality of life to lenalidomide, with no significant differences in global health status.
  • Improvement in social functioning was observed over time, alongside adverse events including infections and other complications in both treatment arms.
  • Randomized trial involving 89 patients with newly diagnosed multiple myeloma assessed quality of life and efficacy across daratumumab versus lenalidomide.
  • Findings support the use of daratumumab as an effective maintenance option for patients with lenalidomide intolerance, possibly influencing future treatment protocols.

Cite This Study

Devlin et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df45https://doi.org/10.1182/blood-2025-2273
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)2025 · 1 citations
  2. 2Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population2025
  3. 3Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study2025 · 2 citations
  4. 4Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age2025 · 4 citations
  5. 5Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma2025